Vertex Pharmaceuticals VRTX shares are trading higher after Argus Research maintained a Buy rating on the stock and raised its price target from $270 to $320.
Vertex Pharmaceuticals discovers and develops small-molecule drugs. The company’s key drugs include Kalydeco, Orkambi, Symdeko and Trikafta.
The health care sector has seen an increase in volatility as companies race to satisfy the increased demand caused by the coronavirus.
Vertex shares were trading higher by 3.92% at $287.86 at time of publication on Friday. The stock has a 52-week high of $288.52 and a 52-week low of $165.23.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
